medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2021, Number 1

<< Back Next >>

Rev Mex Urol 2021; 81 (1)

Correlation study of histologic pattern and clinical stage of testicular tumors with tumor markers

Rodríguez-Valle ED, Maldonado-Ávila M, Rodríguez-Sánchez Y, Arévalo-García F, Jaspersen-Gastelum J, López-Alvarenga JC, Reading-Bernal A, Nava-Palacios J, Rico-Frontana E, Almanza-González MS, Berber-Deseusa AD, Moreno CJC, De los Santos-González JA, Magaña-González JE, Cabrera-Mora NA, Hernández-Hernández RA, Sánchez-Núñez JE

Language: Spanish
References: 23
Page: 1-11
PDF size: 214.23 Kb.


ABSTRACT

Background: Testicular tumor is the most frequent solid tumor in men between 20 and 34 years of age. Testicular tumors can be histologically divided into germ cell tumors, which present in 90–95% of cases, and non-germ cell tumors, which present in around 5%. Tumor markers are crucial for the diagnosis, classification, and prognosis of testicular tumors, as well as for surveillance after treatment.
Objective: To know the actual prevalence of testicular cancer at our service, determine the clinical and pathologic characteristics of testicular cancer, and correlate tumor marker levels with histologic pattern and clinical stage of the disease.
Methodology: A cross-sectional study analyzed the case records of patients with testicular cancer seen at the urology service, within the time frame of January 1, 2014 and December 31, 2018.
Results: Ninety-nine patients with a mean age of 29±8.5 years were included. The most frequent tumors were germ cell tumors, reported in 99% of cases: 50 were mixed germ cell tumors (50.51%), 42 were seminoma (42.42%), and 5 were teratoma (5.05%). The most common TNM combination was T1 N0 M0. The most frequent clinical stage was stage I, followed by stage II, and then stage III. Alpha-fetoprotein was the only tumor marker that was associated with histologic pattern and possible disseminated disease.
Limitations: Small sample size and a low incidence of some of the types of tumor were study limitations.
Originality: Our analysis provides information on testicular cancer in a Latin American population, an infrequently studied cohort.
Conclusions: The most frequent histologic pattern in our patients was mixed germ cell tumor and the most common TNM classification was T1a, N0, M0 and clinical stage I. Alpha-fetoprotein was the only predictive marker for histologic pattern and possible disseminated disease.


REFERENCES

  1. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol. 2010;21(6):1323–60. doi: 10.1093/annonc/mdp530

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332

  3. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol. 2003;170(1):5–11. doi: 10.1097/01.ju.0000053866.68623.da

  4. Verhoeven RHA, Gondos A, Janssen-Heijnen MLG, Saum KU, Brewster DH, Holleczek B, et al. Testicular cancer in Europe and the USA: survival still rising among older patients. Ann Oncol. 2013 Feb;24(2):508–13. doi: 10.1093/ annonc/mds460

  5. Sarıcı H, Telli O, Eroğlu M. Bilateral testicular germ cell tumors. Turk J Urol. 2013;39(4):249– 52. doi: 10.5152/tud.2013.062

  6. Turnbull C, Rahman N. Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour. International Journal of Andrology. 2011;34(4pt2):e86–97. doi: https://doi. org/10.1111/j.1365-2605.2011.01162.x

  7. Greene MH, Kratz CP, Mai PL, Mueller C, Peters JA, Bratslavsky G, et al. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer. 2010;17(2):R109–21. doi: 10.1677/ ERC-09-0254

  8. Bertuccio P, Malvezzi M, Chatenoud L, Bosetti C, Negri E, Levi F, et al. Testicular cancer mortality in the Americas, 1980-2003. Cancer. 2007;109(4):776–9. doi: 10.1002/cncr.22473

  9. Vasdev N, Moon A, Thorpe AC. Classification, epidemiology and therapies for testicular germ cell tumours. Int J Dev Biol. 2013;57(2–4):133– 9. doi: 10.1387/ijdb.130031nv

  10. Ferraro S, Trevisiol C, Gion M, Panteghini M. Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice. Clin Chem. 2018 Feb;64(2):270–8. doi: 10.1373/ clinchem.2017.275263

  11. Lempiäinen A, Hotakainen K, Blomqvist C, Alfthan H, Stenman U-H. Increased human chorionic gonadotropin due to hypogonadism after treatment of a testicular seminoma. Clin Chem. 2007;53(8):1560–1. doi: 10.1373/ clinchem.2007.088518

  12. Morris MJ, Bosl GJ. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol. 2000;163(3):796–801.

  13. Nazeer T, Ro JY, Amato RJ, Park YW, Ordonez NG, Ayala AG. Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases. Oncol Rep. 1998;5(6):1425–9. doi: 10.3892/or.5.6.1425

  14. Kundu SD, Carver BS, Sheinfeld J. Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomy. Urology. 2011;78(4):844–7. doi: 10.1016/j. urology.2011.02.002

  15. Salem M, Gilligan T. Serum tumor markers and their utilization in the management of germ-cell tumors in adult males. Expert Rev Anticancer Ther. 2011;11(1):1–4. doi: 10.1586/era.10.219

  16. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28(20):3388–404. doi: 10.1200/ JCO.2009.26.4481

  17. Matei DV, Vartolomei MD, Renne G, Tringali VML, Russo A, Bianchi R, et al. Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did We Learn? Clin Genitourin Cancer. 2017;15(4):e689–96. doi: 10.1016/j.clgc.2017.01.012

  18. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2017

  19. Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol. 2010;7(11):610–7. doi: 10.1038/nrurol.2010.166

  20. Dieckmann K-P, Richter-Simonsen H, Kulejewski M, Ikogho R, Zecha H, Anheuser P, et al. Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation. UIN. 2018;100(4):409–19. doi: 10.1159/000488284

  21. Miki T, Kamoi K, Fujimoto H, Kanayama H, Ohyama C, Suzuki K, et al. Clinical characteristics and oncological outcomes of testicular cancer patients registered in 2005 and 2008: the first large-scale study from the Cancer Registration Committee of the Japanese Urological Association. Int J Urol. 2014;21(8):S1-6. doi: 10.1111/iju.12441

  22. Powles TB, Bhardwa J, Shamash J, Mandalia S, Oliver T. The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int. 2005;95(9):1197–200. doi: 10.1111/j.1464-410X.2005.05504.x

  23. Cooper DE, L’esperance JO, Christman MS, Auge BK. Testis cancer: a 20-year epidemiological review of the experience at a regional military medical facility. J Urol. 2008;180(2):577–81; discussion 581-582. doi: 10.1016/j.juro.2008.04.032




2020     |     www.medigraphic.com